Safety and metabolism of long-term administration of NIAGEN (Nicotinamide Riboside Chloride) in healthy middle-aged and older adults
Conze D, Brenner C, Kruger CL
Key finding
NR is well tolerated at doses up to 1 g/day over 8 weeks in healthy adults. Source: Conze D, Brenner C, Kruger CL Scientific Reports, 2019.
Summary
8-week, randomized controlled trial of NR at 100, 300, 1,000 mg/day vs. placebo. No clinically meaningful safety signals across the dose range.
For background on the compound studied here, see our NR precursor reference.
Frequently asked questions
- What did Conze et al. (2019) find about NR?
- NR is well tolerated at doses up to 1 g/day over 8 weeks in healthy adults. Source: Conze D, Brenner C, Kruger CL "Safety and metabolism of long-term administration of NIAGEN (Nicotinamide Riboside Chloride) in healthy middle-aged and older adults." Scientific Reports, 2019.
- What kind of study is Conze 2019?
- It is a safety study on NR published in Scientific Reports in 2019. 8-week, randomized controlled trial of NR at 100, 300, 1,000 mg/day vs. placebo. No clinically meaningful safety signals across the dose range.
- Where can I read the full Conze 2019 paper?
- The primary source is available on PubMed (PMID 31316207) and via DOI 10.1038/s41598-019-46120-z.
Access the full paper
Related research
Nature Communications · 2016
Nicotinamide riboside is uniquely and orally bioavailable in mice and humans
NR is orally bioavailable in humans and raises blood NAD+ without flushing.
Cell Reports · 2019
Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome
NR raises tissue NAD+ in aged muscle and shifts mitochondrial transcription.
Nature Communications · 2018
Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults
NR at 1 g/day raises NAD+ ~60% and may reduce systolic BP in adults with Stage 1 hypertension.